Ovid therapeutics Inc (OVID)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.16-8.86%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ovid therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	89,545
EPS	—	-0.084
Annual ending 2026-12-31
Revenue	—	793,750
EPS	—	-0.361
Annual ending 2027-12-31
Revenue	—	470,333
EPS	—	-0.386

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
maintain sufficient capital to fund operations	A supporting condition in Ovid therapeutics Inc's published investment case. The stated target is no need for dilutive capital raises beyond current runway in next 12 months.	Intact	announces dilutive capital raise within next 12 months	Runway extended to 2029 via non-dilutive warrant exercise Ovid cashed in a bet to fund operations into 2029, reinforcing financial runway without new dilutive issuance. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
reduce losses and improve EPS	A primary condition in Ovid therapeutics Inc's published investment case. The stated target is EPS loss narrows by at least 10% in FY27 vs FY26.	Improving	EPS loss does not improve or worsens in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
successful clinical development and regulatory milestones	A primary condition in Ovid therapeutics Inc's published investment case. The stated target is achieve key clinical milestones for OV329 and OV4071 in next 12 months.	Intact	failure to meet clinical or regulatory milestones in next 12 months	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
revenue stabilizes or grows beyond 2026	A primary condition in Ovid therapeutics Inc's published investment case. The stated target is revenue growth >= 0% YoY in FY27.	Improving	revenue growth falls below 0% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.39

$-0.53 → $-0.39 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.53	$187,500	7 / 7
2026-07-25	$-0.53	$187,500	7 / 7
2026-07-26	$-0.53	$187,500	7 / 7
2026-07-27	$-0.53	$187,500	7 / 7
2026-07-28	$-0.53	$187,500	7 / 7
2026-07-29	$-0.53	$187,500	7 / 7
2026-07-30	$-0.45	$166,670	6 / 9
2026-07-31	$-0.53	$187,500	7 / 7
2026-08-01	$-0.53	$187,500	7 / 7
2026-08-02	$-0.45	$166,670	6 / 9
2026-08-03	$-0.45	$166,670	6 / 9
2026-08-04	$-0.45	$166,670	6 / 9
2026-08-05	$-0.44	$166,670	6 / 9
2026-08-06	$-0.44	$166,670	6 / 9
2026-08-07	$-0.52	$187,500	7 / 7
2026-08-08	$-0.44	$166,670	6 / 9
2026-08-09	$-0.44	$166,670	6 / 9
2026-08-10	$-0.44	$166,670	6 / 9
2026-08-12	$-0.44	$166,670	6 / 9
2026-08-13	$-0.52	$187,500	7 / 7
2026-08-14	$-0.52	$187,500	7 / 7
2026-08-15	$-0.52	$187,500	7 / 7
2026-08-16	$-0.52	$187,500	7 / 7
2026-08-17	$-0.52	$187,500	7 / 7
2026-08-18	$-0.52	$187,500	7 / 7
2026-08-19	$-0.52	$187,500	7 / 7
2026-08-20	$-0.41	$279,125	8 / 7
2026-08-21	$-0.41	$319,000	8 / 7
2026-08-22	$-0.41	$372,167	8 / 7
2026-08-23	$-0.41	$372,167	8 / 7
2026-08-24	$-0.41	$372,167	8 / 7
2026-08-25	$-0.41	$372,167	8 / 7
2026-08-26	$-0.41	$372,167	8 / 7
2026-08-27	$-0.41	$372,167	8 / 7
2026-08-28	$-0.41	$372,167	8 / 7
2026-08-29	$-0.41	$372,167	8 / 7
2026-08-30	$-0.41	$372,167	8 / 7
2026-08-31	$-0.41	$372,167	8 / 7
2026-09-01	$-0.41	$372,167	8 / 7
2026-09-02	$-0.41	$372,167	8 / 7
2026-09-03	$-0.41	$366,600	8 / 7
2026-09-04	$-0.41	$366,600	8 / 7
2026-09-05	$-0.42	$305,500	8 / 7
2026-09-06	$-0.42	$305,500	8 / 7
2026-09-07	$-0.42	$305,500	8 / 7
2026-09-08	$-0.42	$305,500	8 / 7
2026-09-09	$-0.42	$305,500	8 / 7
2026-09-10	$-0.42	$305,500	8 / 7
2026-09-11	$-0.42	$305,500	8 / 7
2026-09-12	$-0.41	$319,000	8 / 7
2026-09-13	$-0.41	$319,000	8 / 7
2026-09-14	$-0.41	$319,000	8 / 7
2026-09-15	$-0.41	$319,000	8 / 7
2026-09-16	$-0.41	$319,000	8 / 7
2026-09-17	$-0.41	$319,000	8 / 7
2026-09-18	$-0.41	$319,000	8 / 7
2026-09-19	$-0.41	$319,000	8 / 7
2026-09-20	$-0.41	$319,000	8 / 7
2026-09-21	$-0.41	$319,000	8 / 7
2026-09-22	$-0.41	$319,000	8 / 7
2026-09-23	$-0.41	$319,000	8 / 7
2026-09-24	$-0.41	$319,000	8 / 7
2026-09-25	$-0.41	$319,000	8 / 7
2026-09-26	$-0.41	$319,000	8 / 7
2026-09-27	$-0.41	$319,000	8 / 7
2026-09-28	$-0.41	$319,000	8 / 7
2026-09-29	$-0.41	$319,000	8 / 7
2026-09-30	$-0.41	$319,000	8 / 7
2026-10-01	$-0.41	$319,000	8 / 7
2026-10-02	$-0.41	$319,000	8 / 7
2026-10-03	$-0.41	$319,000	8 / 7
2026-10-04	$-0.41	$319,000	8 / 7
2026-10-05	$-0.41	$319,000	8 / 7
2026-10-06	$-0.40	$319,000	8 / 7
2026-10-07	$-0.40	$319,000	8 / 8
2026-10-08	$-0.40	$319,000	8 / 8
2026-10-09	$-0.40	$319,000	8 / 8
2026-10-10	$-0.40	$319,000	8 / 8
2026-10-11	$-0.39	$279,125	9 / 8
2026-10-12	$-0.39	$279,125	9 / 9
2026-10-13	$-0.39	$279,125	9 / 9
2026-10-14	$-0.39	$279,125	9 / 9
2026-10-15	$-0.39	$279,125	9 / 9
2026-10-16	$-0.39	$470,333	9 / 9
2026-10-17	$-0.39	$470,333	9 / 9
2026-10-18	$-0.39	$470,333	10 / 9
2026-10-19	$-0.39	$470,333	10 / 9
2026-10-20	$-0.39	$470,333	10 / 9
2026-10-21	$-0.39	$470,333	10 / 9
2026-10-22	$-0.39	$470,333	10 / 9
2026-10-23	$-0.39	$470,333	10 / 9
2026-10-24	$-0.39	$470,333	10 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wolfe ResearchOct 15

$5.00New observation · no comparable prior

GuggenheimOct 5

$7.00New observation · no comparable prior

$0$3.85$7.70

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

reduce losses and improve EPSDirect metric needs a verified mapping
successful clinical development and regulatory milestonesQualitative condition
revenue stabilizes or grows beyond 2026Direct metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-27.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ovid therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage biotech, where the case depends on advancing drug candidates rather than established earnings. The long-term thesis is on watch: management is meeting key development and funding milestones, but recent financial performance remains weak and risk is elevated.

What's priced into Ovid therapeutics Inc

The valuation model points to a 2.14-times premium versus peers and an expectations gap of 0.32, though confidence in those estimates is low. The priced-in signal is tagged unjustified, with no fragility gates triggered; the evidence does not show precisely which expectations the market assumes.

What the fundamentals likely do

Near term, OVID remains loss-making, and its recent financial performance sits well below its industry cohort; the latest event list also includes an earnings beat. Over the multi-year view, OV4071 has advanced on schedule, OV329 studies are progressing with further studies planned, and cash and marketable securities rose to support operations into 2029. The next results remain a risk, given the industry's high miss rate and recent peer misses.

What Ovid therapeutics Inc hinges on

The thesis depends on clinical progress, especially the planned OV4071 ketamine challenge study and continued OV329 development across seizure disorders. A guidance cut would be a meaningful negative, while continued strong results and guidance from healthcare peers could support sector momentum; weakening employment data could add pressure to cyclical and healthcare names.